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The emergence of highly aggressive subtypes of human cutaneous squamous cell carcinoma (SCC) often reﬂects increased
autocrine/paracrine TGF-β synthesis and epidermal growth factor receptor (EGFR) ampliﬁcation. Cooperative TGF-β/EGFR
signaling promotes cell migration and induces expression of both proteases and protease inhibitors that regulate stromal
remodeling resulting in the acquisition of an invasive phenotype. In one physiologically relevant model of human cutaneous SCC
progression, TGF-β1+EGF stimulation increases the production of several matrix metalloproteinases (MMPs), among the most
prominent of which is MMP-10—an MMP known to be elevated in SCC in situ. Activation of stromal plasminogen appears to be
critical in triggering downstream MMP activity. Paradoxically, PAI-1, the major physiological inhibitor of plasmin generation, is
also upregulated under these conditions and is an early event in progression of incipient epidermal SCC. One testable hypothesis
proposes that TGF-β1+EGF-dependent MMP-10 elevation directs focalized matrix remodeling events that promote epithelial cell
plasticityandtissueinvasion.IncreasedPAI-1expressionservestotemporallyandspatiallymodulate plasmin-initiatedpericellular
proteolysis, further facilitating epithelial invasive potential. Deﬁning the complex signaling and transcriptional mechanisms that
maintain this delicate balance is critical to developing targeted therapeutics for the treatment of human cutaneous malignancies.
Copyright © 2009 Jennifer Freytag et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. EpithelialSkinCancer Initiation
Nonmelanoma skin cancers (NMSCs) (i.e., basal cell, squa-
mouscell,andMerkelcellcarcinomas)arethemostcommon
human malignancies [1, 2]. In North America alone, >50%
of all neoplasms arise in the skin [3] and the incidence
of NMSC in Australia for the year 2002 was more than
ﬁve times the incidence of all other cancers combined [4].
Relative to other cutaneous tumors, advanced squamous
cell carcinoma (SCC) is aggressive, resistant to localized
therapy with signiﬁcant associated mortality and increasing
in frequency [5].
The emergence of epithelial skin tumors appears causally
linked to ultraviolet (UV) radiation exposure. Speciﬁc UV-B
“signature” base changes (C→To rC C →TT), particularly
in codons 177 (basal cell carcinoma) and 278 (SCC) in
the tumor suppressor p53 gene [6–8], likely occur early
in epidermal carcinogenesis. Indeed, UV-associated p53
mutations are prevalent in solar radiation-induced actinic
keratosis; 10% of these lesions progress to SCC and 60%
of all SCC arise within actinic keratoses [9–11]. Transition
of a normal keratinocyte to an initiated pre- or early
malignant phenotype, in fact, often involves loss- or gain-
of-function mutations in p53, with characteristic karyotypic
changes including gains in chromosomes 7, 9, 18 (early
on) and 3q, 8q, 9q, and 11q in later stages of tumor pro-
gression, ras gene mutation/activation/ampliﬁed expression
(10–30% incidence), and inactivation of cell cycle inhibitors2 Journal of Oncology
Table 1: Transcript levels for select Cancer Pathway genes.
Gene name Symbol Quiescent versus TGF-β1+EGF
Angiopoietin 1 ANGPT1 3.01
Breast cancer 1, early onset BRCA1 −3.18
Cyclin-dependent kinase 2 CDK2 2.46
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 7.41
Interferon α1I F N α15 . 6 6
Interferon β1, ﬁbroblast IFNβ16 . 8 7
Integrin α1I T G α15 . 6 6
Integrin α2I T G α2 18.25
Integrin β1I T G β1 11.71
Integrin β3I T G β3 59.30
Integrin β5I T G β55 . 8 2
Matrix metallopeptidase 1 MMP1 59.30
Matrix metallopeptidase 9 MMP9 55.33
Metastasis associated 1 MTA1 2.19
Metastasis associated 1 family, member 2 MTA2 1.82
Metastasis suppressor 1 MTSS1 5.58
Platelet-derived growth factor β polypeptide PDGFB 9.51
Plasminogen activator, urokinase PLAU 2.64
Plasminogen activator, urokinase receptor PLAUR 8.00
Serpin peptidase inhibitor, clade E (plasminogen activator inhibitor-1) SERPINE1 168.90
Transforming growth factor β1T G F β15 . 5 4
Transforming growth factor β receptor 1 TGF-βR1 3.46
Thrombospondin 1 THBS1 9.25
Tumor necrosis factor receptor superfamily, member 10b TNFRSF10B 2.16
T u m o rn e c r o s i sf a c t o rr e c e p t o rs u p e r f a m i l y ,m e m b e r2 5 T N F R S F 2 5 3 . 5 3
Vascular endothelial growth factor A VEGFA 23.26
[7, 12–15]. While epidermal cancers associated with mutant
ras expression may be cell type-dependent [16], molecular
events that accompany the development of lesional subsets
in both premalignant cutaneous lesions (actinic keratosis)
and SCC [10, 11, 17] are similar. p53 gain-of-function
versus loss-of-function mutations, moreover, may actually
inﬂuence diﬀerent stages in cutaneous SCC progression with
gain-of-function changes associated with acceleration to
SCC in the context of an oncogenic ras gene [14, 18]. At least
one p53-activating gain-of-function mutation (p53R172H)
results in increased skin tumor formation/progression and
metastatic spread [18].
2.EpithelialCellPlasticityand
Tumor Progression
The accumulated genetic/epigenetic changes accompanying
evolution of aggressive subtypes of cutaneous SCC are
intertwined in a complex signaling landscape emanating
from both tumor cells and stromal-derived elements (e.g.,
hepatocyte growth factor (HGF); epidermal growth factor
(EGF); platelet-derived growth factor (PDGF); transforming
growth factor-β (TGF-β)) [19–24]. TGF-β1 is a particularly
robust initiator of epithelial “plasticity” (usually referred to
as epithelial-to-mesenchymal transition or EMT), a likely
facilitator of tumor invasion and metastasis (see, e.g., [22,
24]). The EMT “phenotome” however depends on physi-
ologic context (i.e., embryogenesis, ﬁbrosis/wound healing,
tumor progression), the involved cell type, and the actual
initiating stimulus [24].
Elevated expression of transforming growth factor-
β1( T G F - β1) in the tumor microenvironment appears
causally linked to creation of highly aggressive metastatic
variants [19–23]. Acquired resistance to TGF-β1-mediated
growth suppression, moreover, is frequently accompanied by
mutation, allelic loss, or misregulation of elements within
the TGF-β1 signaling network (e.g., TGF-βRI, TGF-βRII,
SMAD2, SMAD4, the coreceptors endoglin, and betaglycan)
(see, e.g., [25]). Such signaling defects, particularly in later
stage tumors, are often coupled to constitutive epidermal
growth factor receptor (EGFR) activation as a result of
receptor ampliﬁcation and/or autocrine ligand release [26–
30]. The associated reprogramming of gene expression initi-
ates and perpetuates TGF-β1-induced phenotypic plasticity
[21, 31–37].
Recent data mining of the actual repertoire of plastic-
ity genes (i.e., the EMT transcriptome) has signiﬁcantly
enhanced our understanding of the biology of human cuta-
neous tumor progression while also providing a comparativeJournal of Oncology 3
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Figure 1: Combination stimulation with TGF-β1+EGF induces a plastic response in HaCaT II-4 cells.Am o d e ls y s t e mw a sd e v i s e di nw h i c h
small colonies of HaCaT II-4 cells, seeded on tissue culture plastic, were serum-starved followed by addition of TGF-β1 (1ng/mL) + EGF
(10ng/mL). The induced acquisition of a spindle-shaped, highly migratory phenotype, resulted in marked colony dispersal within 24–48
hours. Cell scattering was accompanied by the loss of E-cadherin (green) and α3 integrin (red) immunostaining at cell-cell junctions, and
the gain of several mesenchymal markers, such as α-smooth muscle actin and vimentin with construction of a well-developed vimentin
ﬁlament network. Induced PAI-1 expression (within 6 hours) was a prominent and early feature of growth factor-stimulated EMT.
map of expressed/repressed genes in actinic keratosis and
SCC versus normal skin [38, 39]. Although the spectrum of
likely candidate genes identiﬁed in diﬀerent studies varies,
plasminogen activator inhibitor type-1 (PAI-1; SERPINE1),
the major physiologic regulator of the pericellular plasmin-
generating cascade, has consistently emerged as a prominent
member of the subset of TGF-β1-induced, EMT-associated
genes in transformed human keratinocytes [34, 40]. PAI-
1 is signiﬁcantly increased in epithelial cells undergoing
a mesenchymal-like conversion following activation of the
E-cadherin transcriptional repressors, EMT-inducers, Snail,
Slug, or E47 indicating that expression of this serine
protease inhibitor is a general characteristic of the plastic
phenotype [41]. Use of a novel, physiologically-relevant (i.e.,
p53 mutant, Ha-ras-expressing), dual growth factor (TGF-
β1+EGF)-stimulated model of EMT in transformed human
keratinocytes (HaCaT II-4 cells) (Figure 1)a n dm i c r o a r r a y
proﬁling deﬁned PAI-1 as the most highly upregulated tran-
scriptoftheearlygeneset(Figure 2;Table 1).Theacquisition
of a spindle-like, actively motile, behavior in this system
was preceded by a decrease in E-cadherin immunoreactivity,
the induction of vimentin and α-smooth muscle actin
(Figure 1), and a genetic signature typical of an aggressive
epithelial cell type (Table 1). Ingenuity Pathway analyses of
many of these genes (Figure 2; Table 1) indicate that several
(e.g., MMPs, uPA, uPAR, SERPINE1) are direct targets of
TGF-β1, as well as NF-κB, highlighting complex associations
among EMT, the tumor microenvironment, and the atten-
dant inﬂammatory response. Importantly, such clustergrams
illustrate the highly coordinate and interdependent nature
of the deﬁned pericellular proteolytic cascades involved in
focalized stromal degradation and tumor invasion (see, e.g.,
[34, 35, 38–41]).
Elevated PAI-1 tumor levels signal a poor prognosis
and reduced disease-free survival in patients with various
malignancies including breast, lung, ovarian, and oral SCC
[42–46]. Current data suggest a model in which this SERPIN
maintains an angiogenic “scaﬀold,” stabilizes nascent
capillary vessel structure, and facilitates tumor cell stromal
invasionthroughprecisecontroloftheperitumorproteolytic
microenvironment [42, 47, 48]. Indeed, recent targeting
of PAI-1 expression in endothelial cells and exogenous4 Journal of Oncology
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Figure 2: Microarray transcript proﬁling and pathway analysis of TGF-β1+EGF-impacted genes in HaCaT II-4 keratinocytes.F o c u s e d
microarrays of dual growth factor-stimulated HaCaT II-4 cells revealed the increased expression of mRNAs encoding proteins involved
in angiogenesis, stromal invasion, and control of pericellular proteolysis. PAI-1 transcripts were the most highly upregulated (>168-fold),
induced early (within 6 hours) of stimulation and prior to the onset of colony dispersal. Ingenuity Pathway clustergram mapping describes
potentialfunctionalinteractionsamongthecomplementofinducedgenes.Pathwayanalysesofmanyofthesegenes(seealsoTable 1)indicate
that several including uPA, uPAR, SERPINE1, and the MMPs are TGF-β1 targets and encode key elements in the integrative proteolytic
cascades that regulate focalized stromal degradation and tumor invasion.
introduction of stable PAI-1 variants conﬁrmed that PAI-1
is critical to nascent vessel stabilization and preservation
of collagen matrix integrity [35, 49, 50]. In vivo studies,
moreover, clearly implicate PAI-1 as an important, perhaps
stage-dependent, determinant in cutaneous tumor invasion
and the associated angiogenic response [47, 48, 51, 52]
(Figure 3). PAI-1 likely “titrates” the extent and locale of
collagen matrix remodeling, facilitating tumor invasion
into the stroma while maintaining an angiogenic network
by inhibiting capillary regression. Molecular knockdown
“rescue” strategies, in fact, conﬁrmed PAI-1 to be a positive
regulator of keratinocyte migration and an inhibitor of
plasminogen-induced anoikis [53] .P A I - 1u p r e g u l a t i o ni s
an early event in the progression of incipient epidermal
SCC, often localizing to tumor cells and cancer-associated
myoﬁbroblasts at the invasive front [54–56] and, more
importantly, is a marker with signiﬁcant prognostic
value [43–46]. Identiﬁcation of PAI-1 (Figure 4(a))i n
SCC-proximal α-SMA-positive stromal myoﬁbroblasts
(Figure 4(b)), furthermore, implies a more global involve-
ment as a matricellular modulator of invasive potential
[55–57] consistent with the increasing appreciation of the
role of tumor stromal ﬁbroblasts in cancer progression [58].
2.1. Stromal Remodeling Accompanies the Acquisition of
Epithelial Plasticity. Costimulation of human cutaneous
SCC (HaCaT II-4) cells with TGF-β1+EGF promotes a
plastic transition typical of late-stage tumor progression
[35, 61]( Figure 1). This conversion to a more aggressive
phenotype appears to be due, in part, to deregulated growth
factor signaling and the transcriptional reprogramming
that supports stromal remodeling events [62–69]. Plasmin
generation, in particular, accompanies cooperative TGF-
β1/EGFR signaling during the evolution of keratinocyte cell
plasticity and is a critical event in the downstream activation
ofacomplexandhighlyinterdependentuPA-plasmin-matrix
metalloproteinase (MMP) cascade [35, 70–80]. uPA, uPAR,
and MMP expression levels are, in fact, signiﬁcantly upreg-
ulated in HaCaT II-4 cells following stimulation with TGF-
β1+EGF (e.g., Figure 2). The combination of TGF-β1+EGF,
therefore, augments both matrix deposition, through TGF-
β1-dependent upregulation of ﬁbronectin, laminin, proteo-
glycans, tenascin, thrombospondin and PAI-1 production,
and focal degradation by dependent increases in MMPs-1,
-2, -3, -9, -10, -11, -13, and -21 [35, 66–71, 81–83].
TGF-β1- and/or EGF-stimulated synthesis of the gener-
ally epithelial-restricted MMP-10 (stromelysin-2) [72, 73],Journal of Oncology 5
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Figure 3: Cutaneous carcinoma invasion and tumor angiogenesis
are suppressed in PAI-1−/− mice. Malignant murine (PDVA) ker-
atinocytes, cultured on a collagen gel in a silicone implantation
chamber (top schematic), were transplanted onto PAI-1−/− and
wild-type PAI-1+/+ mice. Tumor implantation in PAI-1−/− hosts
resulted in a dramatic impairment of stromal invasion and failure
to develop a supporting angiogenic network unlike the robust
responsesevidentinwild-typeanimals.Tissuesectionswerestained
with hematoxylin/eosin (two upper panels) or immunostained for
keratin (green; to identify transplanted carcinoma cells) and type
IV collagen (red; to delineate capillary vessel basement membrane
(two lower panels)).
which targets a broad spectrum of matrix components
including collagens types III, IV, and V, gelatin, elastin,
ﬁbronectin,proteoglycansandlaminin, aswellasproMMPs-
1, -7, -8, -9, and -13 [74] is particularly signiﬁcant. SCC of
the head and neck, esophagus, oral cavity, and skin expresses
elevated levels of MMP-10 [75–78]. While not detectable
in intact skin, during cutaneous wound healing MMP-10
is expressed by keratinocytes that comprise the migrating
tongue [79], where its activity appears to be important
in stromal remodeling during cutaneous wound healing
[79]. Despite an inability to cleave collagen type-I, a major
dermal component, MMP-10, promotes plasmin-dependent
collagenolysis by TGF-β1+EGF-stimulated HaCaT II-4 cells
in a 3-dimensional system [35]. MMP-10, in fact, “super-
activates” collagenase 1 (MMP-1), increasing MMP-1-
dependent activity >10-fold compared to its activation by
plasmin alone [72] creating a signiﬁcant proteolytic axis
within the cutaneous environment.
Several MMPs, including MMP-10, are synergistically
increasedfollowingcostimulationofintestinalepithelialcells
with TGF-β1+EGF [80]. In HaCaT II-4 keratinocytes, dual
stimulation with TGF-β1+EGF induces MMP-10 expression
while dramatically enhancing PAI-1 production and stromal
invasion [35]. Since type-1 collagen degradation is essential
for dermal remodeling, cutaneous tumor invasion may well
be considerably dependent on MMP-10 activity. Indeed,
MMP-10 upregulation, concomitant with increased STAT3
phosphorylation, accompanies the development of invasive
behavior in breast cancer [81]. Similarly, EGF-dependent
MMP-10 expression in bladder tumor cells is associated with
changes in STAT3 signaling [82]. While the link between
STAT3 activation and MMP-10 expression in cutaneous
tumor progression remains to be determined, STAT3 over-
expression/activation parallels invasive traits in cutaneous
SCC [83, 84] suggesting that STAT3 may temporally regu-
late expression of proteolytically active components in the
stromal microenvironment. Our studies indicate, moreover,
that PAI-1 regulates MMP-10-dependent collagenolysis in
TGF-β1+EGF-stimulated HaCaT II-4 keratinocytes [35].
Collectively, the current data suggest a model (Figure 5)
in which MMP-10 induction in response to coincuba-
tion with TGF-β1+EGF activates MMPs-1, -7, -8, -9, and
-13 stimulating plasmin-dependent matrix proteolysis. A
corresponding upregulation of PAI-1 provides a sensitive
focalized mechanism for titering the extent and duration of
extracellular matrix degradation consequently sustaining a
stromal scaﬀold necessary for tissue invasion. STAT3 in this
context may promote this phenotype by regulating growth
factor-dependent expression of critical remodeling factors
such as MMP-10 and PAI-1 (Figure 5).
2.2. TGF-β1/EGFR Pathway Integration in PAI-1 Expression
Control. In several common carcinoma types, including
cutaneous SCC, the combination of TGF-β1+EGF eﬀec-
tively initiates and maintains the dramatic morphological
restructuring and genomic responses characteristic of the
plastic phenotype [35, 61, 80]. In particular tumor models,
the addition of EGF serves to activate the ras →raf →
MEK→ERK cascade as a collateral stimulus to TGF-βR-
dependent signaling. Clearly, cooperative, albeit complex,
interactions between TGF-β1- and EGFR-activated path-
ways involving EGFR/pp60c-src,p 2 1 ras and mitogen-activated
extracellular kinase (MEK) [85] and the MAP kinases
ERK/p38 appear mechanistically linked to epithelial tumor
cell plasticity, at least in HaCaT II-4 cells [28, 30, 86–
88]. The nonreceptor tyrosine kinase pp60c-src is, in fact,
a critical intermediate in a TGF-β1-initiated transduction
cascade leading to MEK involvement, PAI-1 transcription,
anddownstreamphenotypicresponses[28,85,86,88].TGF-
β1 complements EGF-mediated signaling to the MAPK/AKT
pathways to eﬀect EMT consistent with the requirement
for oncogenic ras in TGF-β1-induced EMT [89, 90]. Dis-
ruption of TGF-β1-stimulated ERK1/2 phosphorylation and
PAI-1 transcription by src family kinase inhibitors, as
well as blockade of EGFR signaling with AG1478, sug-
gests that pp60c-src, perhaps through phosphorylation of
the Y845 src-kinase EGFR target residue, regulates MEK-
ERK-dependent PAI-1 expression [28, 85, 91]( Figure 6).6 Journal of Oncology
PAI-1
SCC
SCC
(a)
α-SMA
SCC
SCC
(b)
Figure 4: In situ distribution of PAI-1 in an early invasive human cutaneous squamous cell carcinoma. Sections were dually stained for PAI-1
(red;(a))andα-smoothmuscleactin(α-SMA,green;(b)).PAI-1wasevidentintheSCCepitheliumattheinvasivefront(arrows).Prominent
PAI-1-expression also colocalized to α-SMA-positive cells, a marker for myoﬁbroblasts, at the carcinoma periphery. Barbed arrowheads
indicate PAI-1/α-SMA at the tumor perimeter while arrowheads depict PAI-1/α-SMA in stromal cells.
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Figure 5: Proposed mechanistic context for TGF-β1+EGF-enhanced plasmin-dependent collagen matrix remodeling and its contribution to
development of an invasive phenotype. Dual growth factor-stimulated HaCaT II-4 keratinocytes cultured on a three-dimensional collagen gel
upregulate critical stromal remodeling factors that both disrupt and preserve matrix integrity. In the presence of active plasmin, increased
MMP-10 promotes MMP activation and creates a proteolytic axis that accelerates collagen degradation through “superactivation” of MMP-
1. STAT3 phosphorylation may serve as a temporal switch in this process, through its ability to both promote EGF-stimulated proMMP-
10 expression and antagonize induction of TGF-β1 target genes (i.e., PAI-1, ﬁbronectin) [59]. The synergistic upregulation of PAI-1 in
response to TGF-β1+EGF may subsequently shift this proteolytic balance, enabling PAI-1 to “titrate” the extent and locale of collagen matrix
remodeling to facilitate tumor cell stromal invasion. Indeed, PAI-1 induction is an early event in this phenotypic transition and required for
the motile response since PAI-1 knockdown (with siRNA constructs) eﬀectively inhibited TGF-β1+EGF-initiated colony scattering [60].
While the actual mechanism underlying TGF-β1-associated
pp60c-src kinase/EGFR stimulation remains to be deter-
mined, TGF-β1-dependent release of EGFR ligands (e.g.,
HB-EGF,amphiregulinand/orTGF-α)viaMMP-orADAM-
dependent processes is one likely possibility for at least some
cell types [60, 92]. Alternatively, the TGF-β1-stimulated
formation of integrin/FAK/p130cas/EGFR complexes may
initiate ligand-independent EGFR activation and pp60c-src
recruitment [91, 93, 94]. Indeed, in HaCaT cells, TGF-β1
transactivates the EGFR in a complex manner requiring src
kinase signaling and production of reactive oxygen species
but may not involve the shedding of EGFR ligands [30, 95].
The eﬀective blockade of TGF-β1-stimulated ERK1/2 phos-
phorylation and PAI-1 transcription by src kinase-targetingJournal of Oncology 7
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Figure 6:AmodelforT GF -β1inducedP AI-1tr anscription.EmergingstudiessuggestthattranscriptionaloutputsfrombothSMAD2/3aswell
as non-SMAD (e.g., EGFR-MEK/ERK) pathways are absolutely critical for TGF-β1-mediated PAI-1 induction. Activated Src kinases (e.g.,
c-Src), downstream of TGF-β1 receptor, function as an upstream regulator of EGFR transactivation (by Y845 phosphorylation). c-Src also
modulates Caveolin-1Y14 phosphorylation, and likely stimulates Rho/ROCK-dependent maintenance of SMAD2/3 transcriptional activity
(by suppressing nuclear levels or activity of the SMAD2/3 phosphatase PPM1A). ERK1/2 (downstream of EGFR activation), or p38 kinases,
may phosphorylate p53 and the bHLH-LZ upstream stimulatory factor proteins 1/2 (USF1/2) in response to TGF-β1. Indeed, SMAD2/3
appears to cooperate with p53 and USF family transcription factors for maximal TGF-β1-directed PAI-1 gene expression.
pharmacologicagents,aswellastheEGFRinhibitorAG1478,
and the requirement for MEK-ERK signaling for the full
inductive eﬀect of TGF-β1, suggests that pp60c-src,p e r h a p s
through phosphorylation of the Y845 src-speciﬁc EGFR
substrate residue regulates the MEK-ERK-dependent PAI-1
expression transduction cascade [28, 30, 51, 85, 86]. While
speciﬁcmechanismsremaintobeclariﬁed,itisapparentthat
cooperative EGFR signaling is an essential aspect of TGF-β1-
stimulated PAI-1 expression which provides novel insights
as to the impact of TGF-β1 in late-stage human cutaneous
tumor progression.
2.3. PAI-1 Transcription: Links to p53. Members of the
p53 family are critical elements in a subset of TGF-β1
transcriptional responses due, at least in part, to the ability
of MAP kinase-phosphorylated p53 to bind SMAD2 [96–
100]. DNase I footprinting/methylation interference and
oligonucleotide mobility shift analyses conﬁrmed, more-
over, that p53 binds to a recognition motif in the PAI-1
promoter resulting in both p53 sequence-driven reporter
gene transcription and induced expression of the endoge-
nous PAI-1 gene [101]. Two p53 half-sites (AcACATGCCT,
cAGCAAGTCC) [Proﬁle Hidden Markov Model score= 82;
89] likely regulate p53-dependent PAI-1 gene activation
[102]. p53-mediated PAI-1 expression control, moreover, is
likely to involve nontranscriptional mechanisms as well since
p53 binds to a 70 nt sequence on the PAI-1 mRNA 3  UTR
resulting in increased mRNA stabilization [103].
p53 is also required for maximal PAI-1 expression in
response to TGF-β1 since induced transcription is signiﬁ-
cantly attenuated in p53 siRNA knockdown cells [98]a sw e l l
as in p53−/− mouse ﬁbroblasts (Samarakoon and Higgins,
unpublished data). This is consistent with the observation
that p53-deﬁcient lung tumor cells synthesize little or no
PAI-1whilevector-engineeredintroductionofwild-typep53
rescues both basal and inducible PAI-1 expressions [103].
The recent analysis of the upstream region of the PAI-1
gene provides some insight as to the possible mechanisms
underlying p53-dependent PAI-1 gene control. The PAI-1
promoter PE2 region hexanucleotide E box (CACGTG), a
site juxtaposed to 3 SMAD-binding elements, is occupied by
upstream stimulatory factor (USF) in response to TGF-β1
stimulation [85, 104]. Phasing analysis revealed that certain
bHLH-LZ members of the MYC family (including USF)
orient DNA bending toward the minor groove [105]w h i c h
could potentially promote interactions between p53, bound
to its downstream half-site motif, with SMAD2 tethered
to the upstream PE2 region SMAD-binding elements, thus,
providing amolecularbasisforSMAD2/p53complexforma-
tion and subsequent transcriptional activation of the PAI-1
gene (Figure 6).8 Journal of Oncology
2.4. Implications on Cell Growth Control. p53 mutations
occur in 40–60% of all skin cancers [9, 106] suggesting
that direct p53 transcriptional targets (such as the PAI-
1 gene) may be activated, repressed, or dysregulated as a
consequence of p53 mutation with associated loss or gain of
function. Indeed, p53 is a major element in PAI-1 induction
inresponsetoTGF-β1[98]andmaybecriticalparticularlyin
the setting of increased autocrine TGF-β1 expression during
cutaneous SCC progression. The role of PAI-1 in subsequent
tumor progression, however, may be more complex than
previously appreciated. Ectopic expression of wild-type PAI-
1inbreastcancercellsorinp53-deﬁcientmurineandhuman
ﬁbroblasts, in fact, initiates a senescence-like growth arrest
[92,107]whileRNAi-mediatedPAI-1knockdown(PAI-1KD)
or PAI-1 genetic deﬁciency (PAI-1−/− genotype) results in
escape from replicative senescence in primary mouse and
human ﬁbroblasts [107]. Proliferation of PAI-1−/− endothe-
lialcells,andPAI-1KD ﬁbroblastsappearsdue,atleastin part,
to sustained activation of the PI3K-AKT-GSK3β pathway,
increased AKT
Ser473 phosphorylation, nuclear retention of
cyclin D1 [107, 108] and, perhaps, increased inactivation
of the tumor suppressor PTEN [108]. Importantly, PAI-
1−/− mouse embryo ﬁbroblasts (MEFs), PAI-1KD HaCaT
keratinocytes, and PAI-1KD MEFs are resistant to TGF-β1-
initiated growth inhibition although PAI-1 deﬁciency does
not interfere with canonical TGF-β1 signaling such as SMAD
phosphorylation or p21CIP1 and p15INK4B induction [109].
Collectively, these data suggest a multifunctional rela-
tionship between PAI-1 expression and tumor progression.
Elevated PAI-1 levels may inhibit (at least transiently) tumor
cell proliferation while stimulating migration and stromal
invasion by providing a sensitive focalized mechanism for
titering the extent and duration of extracellular matrix
degradation, sustaining a stromal scaﬀold necessary for
tissue invasion. This carefully orchestrated process may
also serve to promote tumor cell survival by preventing
anoikis during the precarious process of cell detachment and
readhesiontoanew,likelyforeign,tissuemicroenvironment.
Importantly,theseﬁndingsunderscorethepotentialdiversity
ofnewmoleculartargetsthatcanbeexploitedfortherapeutic
beneﬁt. Reﬁning the current understanding of PAI-1 gene
regulation, and relevant signaling pathways, may lead to the
discovery of critical regulatory factors that ultimately prove
important in stage-speciﬁc treatment of human cutaneous
malignancies.
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